Methyl 6-phenylpyrazine-2-carboxylate, 95.0%, 250mg

5-Methylpyrimidine-2-carbonitrile, 95.0%, 5g

Tetrahydropyran-3-ylhydrazine dihydrochloride, 97%, 500mg

7-Bromo-2-chloro-6-methoxybenzo[d]thiazole, 95.0%, 100mg

N-(tert-Butyl)hydroxylamine acetate, 95.0%, 10g

2-[3-(2-Chloro-ethoxy)-propyl]-6-methyl-pyridine, 1g

2,6-Dichloro-N-(4-chlorobenzyl)aniline, 98%, 250mg

2-((4'-(Trifluoromethoxy)phenoxy)methyl)phenylboronic acid, 98%, 1g

2-(2-Chloro-4-fluorophenoxy)acetohydrazide, 95.0%, 1g

5-Fluoro-6-methoxynicotinaldehyde, 95.0%, 5g

4-Methoxy-2-methylbenzoic acid, 98.0%, 100g

iScope IS.1158-PLPHi Biocular for phase contrast with Plan phase IOS objectives and Rackless cross stage (infinity - ergonomic tilting head)

?-Cyclodextrin, 95%, 10g